These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 35253621)
1. An integrated computational approach to screening of alkaloids inhibitors of TBX3 in breast cancer cell lines. Paul A; Limon MBH; Hossain MM; Raza MT J Biomol Struct Dyn; 2023 Apr; 41(7):3025-3041. PubMed ID: 35253621 [TBL] [Abstract][Full Text] [Related]
2. Potential target identification for breast cancer and screening of small molecule inhibitors: A bioinformatics approach. Agarwal S; Kashaw SK J Biomol Struct Dyn; 2021 Apr; 39(6):1975-1989. PubMed ID: 32186248 [TBL] [Abstract][Full Text] [Related]
3. The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer. Krstic M; Macmillan CD; Leong HS; Clifford AG; Souter LH; Dales DW; Postenka CO; Chambers AF; Tuck AB BMC Cancer; 2016 Aug; 16(1):671. PubMed ID: 27553211 [TBL] [Abstract][Full Text] [Related]
4. TBX3 promotes progression of pre-invasive breast cancer cells by inducing EMT and directly up-regulating SLUG. Krstic M; Kolendowski B; Cecchini MJ; Postenka CO; Hassan HM; Andrews J; MacMillan CD; Williams KC; Leong HS; Brackstone M; Torchia J; Chambers AF; Tuck AB J Pathol; 2019 Jun; 248(2):191-203. PubMed ID: 30697731 [TBL] [Abstract][Full Text] [Related]
5. TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. Fan W; Huang X; Chen C; Gray J; Huang T Cancer Res; 2004 Aug; 64(15):5132-9. PubMed ID: 15289316 [TBL] [Abstract][Full Text] [Related]
6. Isoform-specific promotion of breast cancer tumorigenicity by TBX3 involves induction of angiogenesis. Krstic M; Hassan HM; Kolendowski B; Hague MN; Anborgh PH; Postenka CO; Torchia J; Chambers AF; Tuck AB Lab Invest; 2020 Mar; 100(3):400-413. PubMed ID: 31570773 [TBL] [Abstract][Full Text] [Related]
8. The special stemness functions of Tbx3 in stem cells and cancer development. Dong L; Lyu X; Faleti OD; He ML Semin Cancer Biol; 2019 Aug; 57():105-110. PubMed ID: 30268432 [TBL] [Abstract][Full Text] [Related]
9. Regulation of the T-box transcription factor Tbx3 by the tumour suppressor microRNA-206 in breast cancer. Amir S; Simion C; Umeh-Garcia M; Krig S; Moss T; Carraway KL; Sweeney C Br J Cancer; 2016 May; 114(10):1125-34. PubMed ID: 27100732 [TBL] [Abstract][Full Text] [Related]
10. The roles and regulation of TBX3 in development and disease. Khan SF; Damerell V; Omar R; Du Toit M; Khan M; Maranyane HM; Mlaza M; Bleloch J; Bellis C; Sahm BDB; Peres J; ArulJothi KN; Prince S Gene; 2020 Feb; 726():144223. PubMed ID: 31669645 [TBL] [Abstract][Full Text] [Related]
11. TBX3 over-expression causes mammary gland hyperplasia and increases mammary stem-like cells in an inducible transgenic mouse model. Liu J; Esmailpour T; Shang X; Gulsen G; Liu A; Huang T BMC Dev Biol; 2011 Oct; 11():65. PubMed ID: 22039763 [TBL] [Abstract][Full Text] [Related]
12. Chemical Characterization, Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087 [TBL] [Abstract][Full Text] [Related]
13. [Expression of TBX3 mRNA and its role in the pathogenesis and metastasis of breast cancer]. Chen ZH; Lü GM; Ji TH Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan; 29(1):87-9. PubMed ID: 19218121 [TBL] [Abstract][Full Text] [Related]
14. Structure-based virtual screening, pharmacokinetic prediction, molecular dynamics studies for the identification of novel EGFR inhibitors in breast cancer. Anbuselvam M; Easwaran M; Meyyazhagan A; Anbuselvam J; Bhotla HK; Sivasubramanian M; Annadurai Y; Kaul T; Pappusamy M; Balasubramanian B J Biomol Struct Dyn; 2021 Aug; 39(12):4462-4471. PubMed ID: 32567493 [TBL] [Abstract][Full Text] [Related]
15. Ligand and structure based virtual screening of chemical databases to explore potent small molecule inhibitors against breast invasive carcinoma using recent computational technologies. Agarwal S; Dixit A; Kashaw SK J Mol Graph Model; 2020 Jul; 98():107591. PubMed ID: 32234678 [TBL] [Abstract][Full Text] [Related]
16. In Silico Targeting Human Multidrug Transporter ABCG2 in Breast Cancer: Database Screening, Molecular Docking, and Molecular Dynamics Study. Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Mekhemer GAH; Shawky AM; Moustafa MF; Atia MAM Mol Inform; 2022 Feb; 41(2):e2060039. PubMed ID: 34491628 [TBL] [Abstract][Full Text] [Related]
18. Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach. Lamichhane S; Rai RP; Khatri A; Adhikari R; Shrestha BG; Shrestha SK J Biomol Struct Dyn; 2023 Feb; 41(3):897-911. PubMed ID: 34957911 [TBL] [Abstract][Full Text] [Related]
19. TOPK promotes epithelial-mesenchymal transition and invasion of breast cancer cells through upregulation of TBX3 in TGF-β1/Smad signaling. Lee YJ; Park JH; Oh SM Biochem Biophys Res Commun; 2020 Jan; 522(1):270-277. PubMed ID: 31757421 [TBL] [Abstract][Full Text] [Related]
20. Carboxymuconolactone decarboxylase is a prospective molecular target for multi-drug resistant Acinetobacter baumannii-computational modeling, molecular docking and dynamic simulation studies. Rana S; Skariyachan S; Uttarkar A; Niranjan V Comput Biol Med; 2023 May; 157():106793. PubMed ID: 36944292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]